Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-03-14-Speech-2-151"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-03-14"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20060314.21.2-151"2
lpv:hasSubsequent	lp_eu:2006-03-14-Speech-2-1522
lpv:speaker	lp:Françoise Grossetête2
lpv:spokenAs	vice-chair; EPP-ED (2004-07-20--2007-02-14)3 substitute; ITRE (2004-07-22--2007-01-14)3 unknown; Union pour un Mouvement Populaire (2004-07-20--2009-07-13)3 member; ENVI (2004-07-21--2007-01-14)3 member; Delegation to the Euro-Mediterranean Parliamentary Assembly (2004-09-15--2009-07-13)3 member; Delegation for relations with the Gulf States, including Yemen (2004-09-15--2007-03-13)3
lpv:translated text	". I voted in favour of this text. We must have a firm Community strategy with regard to mercury. Having said that, being firm also means being realistic. Merthiolate, which contains mercury, is used as a preservative in some medicines, including in vaccines. There are around 1 million doses of vaccine that are produced using merthiolate as a decontamination agent. That represents 0.0000003% of the mercury used annually in Europe. In view of the tremendously positive impact that vaccinations have on public health, including in developing countries, it would not therefore be justifiable to impose an immediate ban on the use of this product in vaccines. For all that, it is advisable to encourage research into alternative methods so as to reduce or eliminate the future use of merthiolate. I would also point out that, under pharmaceutical legislation, manufacturers must prove that their products do not harm the environment."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph